Natural Capsules Q3 FY26 Results: Revenue Declines 18%, PAT Drops 6833%
Natural Capsules reported Q3 FY26 results with revenue down 18% and PAT down 6833% YoY. Puducherry unit operations were impacted by regulatory issues. API fermentation block scale-up faced challenges. US trade tariffs have eased. For 9MFY26, revenue fell 14% and PAT by 20458%.
The announcement details significant financial underperformance and operational challenges, including regulatory issues and delays in scaling up new business ventures, which have a material impact on the company's profitability and future outlook.
The company reported significant year-on-year declines in both revenue and profit for the quarter and nine-month period, primarily due to operational disruptions and challenges in scaling up new business segments.
Natural Capsules Limited announced its un-audited standalone and consolidated financial results for the quarter ended December 31st, 2025. The company reported a revenue decline of 18% for the quarter, with PAT dropping significantly by 6833%.
The Executive Director, Mr. Sunil Mundra, commented that the capsules business operations were impacted by a temporary shutdown of the Puducherry unit due to regulatory action concerning its manufacturing and sales licenses. Shipments were deferred, with spillover expected to reflect in Q4FY26 performance. Input costs and realizations remained stable, and US trade tariffs impacting HPMC capsules have been eased, restoring visibility for growth in the US market.
On the API side, scaling up the fermentation block has taken longer than anticipated, presenting challenges in consistent commercial scale output, which has weighed on consolidated profitability. The company is discussing a calibrated strategy with suitable partners to utilize the fermentation block on a contractual basis. These discussions are at an advanced stage.
For the nine months ended December 31st, 2025, revenue saw a decline of 14%, while PAT dropped by 20458%. The company expects a meaningful improvement in the current quarter with both plants running and demand normalizing.
What to do with a filing like this
Natural Capsules Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natural Capsules Limited. Read the original for the full detail.